Design and optimization of selective azaindole amide M 1 positive allosteric modulators-Reference-Cited by-同舟云学术

Design and optimization of selective azaindole amide M 1 positive allosteric modulators

Published:2016-01 Issue:2 Volume:26 Page:650-655
ISSN:0960-894X
Container-title:Bioorganic & Medicinal Chemistry Letters
language:en
Short-container-title:Bioorganic & Medicinal Chemistry Letters

Author:

Davoren Jennifer E.,O’Neil Steven V.,Anderson Dennis P.,Brodney Michael A.,Chenard Lois,Dlugolenski Keith,Edgerton Jeremy R.,Green Michael,Garnsey Michelle,Grimwood Sarah,Harris Anthony R.,Kauffman Gregory W.,LaChapelle Erik,Lazzaro John T.,Lee Che-Wah,Lotarski Susan M.,Nason Deane M.,Obach R. Scott,Reinhart Veronica,Salomon-Ferrer Romelia,Steyn Stefanus J.,Webb Damien,Yan Jiangli,Zhang Lei

Publisher

Elsevier BV

Subject

Organic Chemistry,Clinical Biochemistry,Drug Discovery,Pharmaceutical Science,Molecular Biology,Molecular Medicine,Biochemistry

Reference26 articles.

1. Overview of Muscarinic Receptor Subtypes

2. Effects of Xanomeline, a Selective Muscarinic Receptor Agonist, on Cognitive Function and Behavioral Symptoms in Alzheimer Disease

3. Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia

4. A Selective Allosteric Potentiator of the M1 Muscarinic Acetylcholine Receptor Increases Activity of Medial Prefrontal Cortical Neurons and Restores Impairments in Reversal Learning

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A golden age of muscarinic acetylcholine receptor modulation in neurological diseases;Nature Reviews Drug Discovery;2024-08-14

2. Current Findings and Potential Mechanisms of KarXT (Xanomeline–Trospium) in Schizophrenia Treatment;Clinical Drug Investigation;2024-06-21

3. Modern synthesis of cognitive enhancers: cholinergic ligands;Russian Chemical Bulletin;2023-04

4. Intramolecular Hydrogen Bonding: Shaping Conformers' Structure and Stability;Spectroscopy and Computation of Hydrogen‐Bonded Systems;2022-12-06

5. Opportunities and challenges for the development of M ₁ muscarinic receptor positive allosteric modulators in the treatment for neurocognitive deficits;British Journal of Pharmacology;2022-12-04